Fernando Hurtado de Mendoza

Learn More
BACKGROUND This randomized phase II trial was designed to compare the rate of pathologic complete response (pCR) induced by neoadjuvant cyclophosphamide plus doxorubicin (AC) followed by ixabepilone or paclitaxel in women with early stage breast cancer (BC). Expression of βIII-tubulin as a predictive marker was also evaluated. PATIENTS AND METHODS Women(More)
e21100 Background: Lymphopenia has been shown to be an important prognostic factor for survival in patients with lymphomas and solid tumors. The aim of this study was to evaluate if lymphopenia is a prognostic factor for survival in patients with locally advanced breast cancer after relapse or progression of disease. METHODS We retrospectively evaluated(More)
e21096 Background: It has been suggested that lymphopenia is an important prognostic factor for survival in patients with advanced breast cancer. The aim of this study was to evaluate if lymphopenia could be a predictive factor of responsiveness to preoperative treatment in patients with locally advanced breast cancer. METHODS We retrospectively evaluated(More)
e18524 Background: Epstein-Barr virus (EBV) is an oncovirus associated with several lymphomas. Quantification of EBV viral loads has been reported as a potential biomarker for EBV+ lymphoma. The goal of our study was to detect whole blood EBV DNA viral load at lymphoma diagnosis and correlate it with expression of EBV-encoded RNA (EBER) in tumor tissue. (More)
e18538 Background: EBV+ diffuse large B-cell lymphoma (DLBCL) of the elderly is a new entity included in the WHO Classification. It usually affects elderly patients and has a poor survival, and it is believed to be related to immunosenescence. The goal of this study was to evaluate clinical characteristics and survival of EBV+ DLBCL of the elderly from our(More)
e19542 Background: EBV positive diffuse large B cell lymphoma of the elderly is a new entity included in the Fourth edition of WHO Classification. It usually affects elderly patients and has a poor survival. It believed to be related to immunesenescence. AIM The goal of this study was to evaluate clinical characteristics and survival of EBV positive(More)
Primary colorectal lymphoma is a very rare disease. Primary colorectal lymphoma of diffuse large B-cells is a more frequent subtype representing 1% of all colon diseases. In a retrospective study, the clinical characteristics and treatment course of primary colorectal lymphoma of diffuse large B-cells between 1997 and 2003 were reviewed. According to(More)
  • 1